Patents by Inventor Immaculada Margarit Y Ros
Immaculada Margarit Y Ros has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240424078Abstract: A method of immunizing a human female subject to decrease the risk of Group B Streptococcus (GBS) disease in an infant born to the subject, by providing a priming dose of a GBS vaccine and, more than thirty days after the priming dose, providing a boosting dose of a GBS vaccine.Type: ApplicationFiled: July 2, 2024Publication date: December 26, 2024Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Zourab BEBIA, Bartholomew CORSARO, David Jeffrey DRIVER, Ilse DIEUSSAERT, Ouzama HENRY, Immaculada MARGARIT-Y-ROS
-
Publication number: 20230321213Abstract: The present invention relates to the field of neisserial vaccine compositions (particularly gonococcal vaccine compositions) and the use of such compositions in medicine. More particularly, the present invention relates to genetically modified gonococci of strain FA1090 and outer membrane vesicles obtained therefrom. The invention also provides a process for preparing the genetically modified gonococci of the invention as well as immunogenic compositions and vaccines comprising the outer membrane vesicles of the invention.Type: ApplicationFiled: September 9, 2021Publication date: October 12, 2023Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Isabel DELANY, Giulia GIORDANO, Rosanna LEUZZI, Immaculada MARGARIT Y ROS
-
Publication number: 20230248839Abstract: The present invention is directed towards conjugates comprising fragments of the capsular polysaccharide of Type III Group B Streptococcus (GBS). Suitable fragments may be produced synthetically or by depolymerisation of native polysaccharide.Type: ApplicationFiled: February 15, 2023Publication date: August 10, 2023Applicant: GSK VACCINES S.R.L.Inventors: Roberto ADAMO, Francesco BERTI, Filippo CARBONI, Immaculada MARGARIT Y ROS
-
Publication number: 20230210975Abstract: Methods of inducing an immunogenic response against a bacterial polysaccharide or oligosaccharide, and constructs and compositions for use in such methods.Type: ApplicationFiled: June 11, 2021Publication date: July 6, 2023Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Roberto ADAMO, Filippo CARBONI, Roberta COZZI, Immaculada MARGARIT Y ROS, Maria Rosaria ROMANO
-
Patent number: 11612664Abstract: The present invention is directed towards conjugates comprising fragments of the capsular polysaccharide of Type III Group B Streptococcus (GBS). Suitable fragments may be produced synthetically or by depolymerisation of native polysaccharide.Type: GrantFiled: March 16, 2017Date of Patent: March 28, 2023Assignee: GSK VACCINES S.R.L.Inventors: Roberto Adamo, Francesco Berti, Filippo Carboni, Immaculada Margarit Y Ros
-
Publication number: 20200405871Abstract: The present invention is directed towards conjugates comprising fragments of the capsular polysaccharide of Type III Group B Streptococcus (GBS). Suitable fragments may be produced synthetically or by depolymerisation of native polysaccharide.Type: ApplicationFiled: March 16, 2017Publication date: December 31, 2020Applicant: GSK VACCINES S.R.L.Inventors: Roberto ADAMO, Francesco BERTI, Filippo CARBONI, Immaculada MARGARIT Y ROS
-
Publication number: 20200254083Abstract: A method of immunising a human female subject to decrease the risk of Group B Streptococcus (GBS) disease in an infant born to the subject, by providing a priming dose of a GBS vaccine and, more than thirty days after the priming dose, providing a boosting dose of a GBS vaccine.Type: ApplicationFiled: June 14, 2018Publication date: August 13, 2020Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Zourab BEBIA, Bartholomew CORSARO, David Jeffrey DRIVER, Ilse DIEUSSAERT, Ouzama HENRY, Immaculada MARGARIT-Y-ROS
-
Publication number: 20200030430Abstract: Chimeric capsular polysaccharides, conjugates comprising such chimeric capsular polysaccharides, and pharmaceutical compositions thereof. Further aspects include methods for immunising a subject against infection by administration of such polysaccharides, conjugates, or compositions.Type: ApplicationFiled: June 30, 2016Publication date: January 30, 2020Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Edmondo CAMPISI, Immaculada MARGARIT Y ROS, Roberto ROSINI
-
Patent number: 10286055Abstract: Methods for raising an immune response in a mammal, by administration of an immunogenic composition comprising capsular saccharides from Streptococcus agalactiae (GBS) serotypes conjugated to carrier proteins.Type: GrantFiled: November 21, 2017Date of Patent: May 14, 2019Assignee: GlaxosmithKline Biologicals SAInventors: Guido Grandi, Immaculada Margarit Y Ros, Domenico Maione
-
Patent number: 10245310Abstract: The invention provides a conjugate comprising an antigen and a carrier molecule, wherein the carrier molecule comprises a BP-2a antigen and a spb1 antigen. BP-2a and spb1 are Streptococcus agalactiae antigens. The conjugate may be used in a method for raising an immune response in a mammal, the method comprising administering the conjugate to the mammal. Also provided are pharmaceutical compositions, particularly vaccines, comprising the conjugate.Type: GrantFiled: August 5, 2015Date of Patent: April 2, 2019Assignee: GlaxoSmithKline Biologicals SAInventors: Francesco Berti, Roberta Cozzi, Domenico Maione, Cira Daniela Rinaudo, Immaculada Margarit Y Ros, Guido Grandi
-
Patent number: 10150979Abstract: The invention relates to bacterial mutants, particularly from Streptococcus agalactiae, that secrete capsular polysaccharide and methods of purifying the secreted bacterial capsular polysaccharides from culture medium. The extracted polysaccharides are useful for producing vaccines comprising the polysaccharides alone or conjugated to proteins.Type: GrantFiled: May 5, 2015Date of Patent: December 11, 2018Assignee: GlaxoSmithKline Biologicals SAInventors: Evita Balducci, Francesco Berti, Valdemar Robert Janulczyk, Immaculada Margarit Y Ros, Chiara Toniolo
-
Publication number: 20180104324Abstract: Methods for raising an immune response in a mammal, by administration of an immunogenic composition comprising capsular saccharides from Streptococcus agalactiae (GBS) serotypes conjugated to carrier proteins.Type: ApplicationFiled: November 21, 2017Publication date: April 19, 2018Applicant: GLAXOSMITHKLIINE BIOLOGICALS SAInventors: Guido Grandi, Immaculada Margarit Y Ros, Domenico Maione
-
Patent number: 9855324Abstract: The invention provides an immunogenic composition comprising one or more GBS conjugates and one or more antigens selected from: a) cellular or acellular pertussis antigen, b) a tetanus toxoid, c) a diphtheria toxoid and d) an inactivated polio virus antigen, wherein each GBS conjugate is a group B streptococcus capsular saccharide conjugated to a carrier protein. The invention also provides a method for raising an immune response in a patient, comprising the step of administering to the patient a composition of the invention.Type: GrantFiled: October 3, 2013Date of Patent: January 2, 2018Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Mario Contorni, Guido Grandi, Domenico Maione, Immaculada Margarit Y Ros
-
Patent number: 9855325Abstract: The invention provides an immunogenic composition comprising: a) a conjugate that is a capsular saccharide from GBS serotype Ia conjugated to a carrier protein; b) a conjugate that is a capsular saccharide from GBS serotype Ib conjugated to a carrier protein; c) a conjugate that is a capsular saccharide from GBS serotype III conjugated to a carrier protein; d) a conjugate that is a capsular saccharide from GBS serotype II conjugated to a carrier protein; and e) a conjugate that is a capsular saccharide from GBS serotype V conjugated to a carrier protein.Type: GrantFiled: October 3, 2013Date of Patent: January 2, 2018Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Guido Grandi, Immaculada Margarit Y Ros, Domenico Maione
-
Patent number: 9764027Abstract: The present invention provides an outer membrane vesicle (OMV) from a Gram-negative bacterium, comprising at least one heterologous protein that is free in the lumen of the OMV, wherein the OMV is capable of eliciting an immune response to the heterologous protein when administered to a mammal. The invention also provides methods for preparing the OMVs of the invention, pharmaceutical compositions comprising the OMVs of the invention, especially immunogenic compositions and vaccines, and methods of generating an antibody immune response in a mammal using OMVs.Type: GrantFiled: September 18, 2013Date of Patent: September 19, 2017Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Guido Grandi, Immaculada Margarit Y Ros, Emiliano Chiarot
-
Publication number: 20170224803Abstract: The invention provides a conjugate comprising an antigen and a carrier molecule, wherein the carrier molecule comprises a BP-2a antigen and a spb1 antigen. BP-2a and spb1 are Streptococcus agalactiae antigens. The conjugate may be used in a method for raising an immune response in a mammal, the method comprising administering the conjugate to the mammal. Also provided are pharmaceutical compositions, particularly vaccines, comprising the conjugate.Type: ApplicationFiled: August 5, 2015Publication date: August 10, 2017Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Francesco BERTI, Roberta COZZI, Domenico MAIONE, Cira Daniela RINAUDO, Immaculada MARGARIT Y ROS, Guido GRANDI
-
Publication number: 20170073716Abstract: The invention relates to bacterial mutants, particularly from Streptococcus agalactiae, that secrete capsular polysaccharide and methods of purifying the secreted bacterial capsular polysaccharides from culture medium. The extracted polysaccharides are useful for producing vaccines comprising the polysaccharides alone or conjugated to proteins.Type: ApplicationFiled: May 5, 2015Publication date: March 16, 2017Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Evita BALDUCCI, Francesco BERTI, Valdemar Robert JANULCZYK, Immaculada MARGARIT Y ROS, Chiara TONIOLO
-
Publication number: 20160137702Abstract: The invention provides mutants of GAS57 (Spy0416) which are unable to cleave IL-8 and similar substrates but which still maintain the ability to induce protection against S. pyogenes. The invention also provides antibodies which specifically bind to GAS57 and which inhibit its ability to cleave IL-8 and similar substrates. The mutants are useful, inter alia, in vaccine compositions to induce protection against S. pyogenes. The antibodies are useful, e.g., as therapeutics for treating S. pyogenes infections.Type: ApplicationFiled: August 7, 2015Publication date: May 19, 2016Inventors: Immaculada Margarit Y Ros, Guido Grandi, Chiara Zingaretti
-
Publication number: 20150273042Abstract: The invention provides methods of forming pili in vitro and proteins suitable for use in these methods. The invention also provides pili produced by these methods and compositions comprising these pili for the treatment and prevention of bacterial disease, in particular of conditions caused by Streptococcus.Type: ApplicationFiled: February 23, 2013Publication date: October 1, 2015Inventors: Domenico Maione, Immaculada Margarit Y Ros, Roberta Cozzi, Cira Daniela Rinaudo, Maddalena Lazzarin, Francesca Zerbini
-
Publication number: 20150231232Abstract: The present invention provides an outer membrane vesicle (OMV) from a Gram-negative bacterium, comprising at least one heterologous protein that is free in the lumen of the OMV, wherein the OMV is capable of eliciting an immune response to the heterologous protein when administered to a mammal. The invention also provides methods for preparing the OMVs of the invention, pharmaceutical compositions comprising the OMVs of the invention, especially immunogenic compositions and vaccines, and methods of generating an antibody immune response in a mammal using OMVs.Type: ApplicationFiled: September 18, 2013Publication date: August 20, 2015Inventors: Guido Grandi, Immaculada Margarit Y Ros,, Emiliano Chiarot